Molecular Partners AG - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MOLN Nasdaq 2830 www.molecularpartners.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Molecular Partners AG

Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70 - Oct 21st, 2026 11:00 pm
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study - Aug 24th, 2026 11:00 pm
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma - Jul 15th, 2026 11:00 pm
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - Jul 14th, 2026 11:00 pm
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics - Jul 5th, 2026 11:00 pm
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 - Jul 1st, 2026 11:00 pm
European Penny Stocks To Watch In June 2026 - Jun 10th, 2026 12:04 am
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 - May 30th, 2026 6:00 am
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - May 26th, 2026 2:00 pm
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 - May 12th, 2026 2:00 pm
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences - May 3rd, 2026 11:00 pm
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling - May 1st, 2026 5:00 am
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 - Apr 19th, 2026 10:00 am